Responses
Scientific Abstracts
Oral Presentations
Progress in myositis and scleroderma research - I
OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC)
Compose a Response to This Article
Other responses
No responses have been published for this article.